BOULDER, Colo., Aug. 19, 2016 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that results from a Phase 2 study of ARRY-797 will be presented at the 2016 European Society of Cardiology (ESC) Congress, which will be held August 27 – 31, 2016 in Rome, Italy.
POSTER PRESENTATION
Title: | Phase 2 study of A797, an oral, selective p38 mitogen-activated protein kinase inhibitor, in patients with lamin A/C-related dilated cardiomyopathy (Abstract #P4981) |
Presenter: | Calum A. MacRae, MD |
Date: | Tuesday, August 30, 10:19 a.m. CEST |
Updated and additional data will be provided at the conference beyond what is included in the abstract.
All abstracts can be accessed through the ESC website, or on this web page: http://spo.escardio.org/default.aspx?eevtid=1127.
The ARRY-797 abstract can be found by clicking this LINK.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Five registration studies are currently advancing related to three cancer drugs. These programs include binimetinib (MEK162), encorafenib (LGX818) and selumetinib (AstraZeneca). For more information on Array, please go to www.arraybiopharma.com.
CONTACT: | Tricia Haugeto |
(303) 386-1193 | |
Logo - http://photos.prnewswire.com/prnh/20121029/LA02195LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/array-biopharma-announces-clinical-data-presentation-on-arry-797-at-the-2016-european-society-of-cardiology-congress-300316027.html
SOURCE Array BioPharma
